The condition formerly known as polycystic ovary syndrome (PCOS) has been officially renamed. The new name is polyendocrine metabolic ovarian syndrome, or PMOS. The change follows a global consensus process that included input from more than 14,000 survey responses and 56 organizations worldwide.
The old name was misleading. The condition does not actually involve pathological ovarian cysts, despite what the name suggested. What appeared as cysts on some ultrasounds were immature follicles, a symptom of hormonal dysfunction rather than the cause. By focusing on the ovaries, the old terminology obscured the condition’s true nature as a multi-system syndrome involving hormones, metabolism, and ovarian function.
Research confirms the diagnostic gap this caused. A 2025 study found that while population-based data show PCOS prevalence of 4 to 19.6 percent, health system records capture only 0.2 to 5.2 percent. Studies also show that Black patients are 69 percent more likely to have a missed diagnosis compared to non-Hispanic White patients.
The new name breaks down into three components. “Polyendocrine” means the condition involves multiple hormone systems, including reproductive hormones, androgens like testosterone, insulin, and neuroendocrine hormones that affect mood and metabolism. “Metabolic” refers to insulin resistance, a core feature for most women with this condition, carrying significant downstream risks. “Ovarian” captures irregular cycles, anovulation, and fertility challenges, now understood as one piece of a larger puzzle.
A 2025 study describes a bidirectional relationship between insulin resistance and PMOS symptoms like excess androgens and ovulatory dysfunction. PMOS itself also increases the risk of type 2 diabetes. Evidence shows the condition has reproductive, metabolic, and psychological impacts across the lifespan.
When clinicians heard “PCOS,” they looked for ovarian cysts and menstrual irregularities. The new name widens the diagnostic lens. Many women with PMOS do not fit the narrow classic presentation. Some have regular periods. Others present with irregular cycles but no visible follicles on ultrasound. Symptoms like insulin resistance, elevated androgens, acne, hair changes, or metabolic markers point to the same underlying dysfunction.
The hope is that reframing the condition as metabolic and endocrine, rather than simply gynecological, will prompt earlier and more comprehensive screening. A woman presenting with unexplained weight gain, fatigue, and skin changes might now be evaluated for PMOS rather than having symptoms dismissed or sent to separate specialty visits.
For those already diagnosed, the name change validates what many have long known. The condition is not just about the ovaries. It is a whole-body condition that deserves whole-body care, including metabolic screening, cardiovascular risk assessment, and attention to mental health. For those who suspect something is off but have not gotten answers, the evolving understanding of PMOS may help. Patients can ask healthcare providers about comprehensive hormone and metabolic testing, not just an ultrasound.
The renaming reflects decades of research showing this condition extends far beyond the ovaries. For millions of women affected worldwide, the new terminology may lead to earlier diagnosis, more comprehensive care, and better recognition of the metabolic and hormonal factors that shape women’s health.
